Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdNEU3
- Development stage
- Preclinical
- Lead developer
- Miyagi Prefectural Cancer Center
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
AdNEU3 is an adenoviral gene therapy vector encoding human sialidase-3 (NEU3), a plasma membrane-associated sialidase that preferentially hydrolyzes sialic acid residues on gangliosides. Developed by researchers at Tohoku University and the Miyagi Prefectural Cancer Center, AdNEU3 is designed to overexpress NEU3 in the liver. In preclinical models of type 2 diabetes and diet-induced obesity, hepatic overexpression of NEU3 modifies ganglioside composition (specifically reducing GM3, a negative regulator of insulin signaling) to enhance insulin receptor substrate 1 (IRS-1) tyrosine phosphorylation, thereby improving insulin sensitivity and glucose tolerance.
- Other names
- adenovirus encoding human NEU3adenovirus encoding human sialidase-3adenovirus-mediated human NEU3
02
Targets
GM3 (Ganglioside GM3)
Beyond the preview
Go deeper on AdNEU3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdNEU3.